Evaluation of long-term outcome following therapeutic mammaplasty: the effect of wound complication on initiation of adjuvant therapy and subsequent oncological outcome

• DOI: 10.1308/rcsann.2023.0095
• Publication Date: 2024-05-15T07:51:13Z
• Authors: R Rampal; S Jones; W Hogg; B Rengabashyam; B Hogan; R Achuthan; B Kim
• Keywords: Adjuvant Therapy

Therapeutic mammaplasty (TM) facilitates large tumour resection while maintaining optimal aesthetic outcome. It carries higher wound complication risks, which may delay adjuvant therapy initiation. Whether this affects oncological outcome requires evaluation. Data were collected for consecutive patients receiving TM at the Leeds breast unit (2009-2017). A prospectively maintained database was used to determine characteristics, rates, receipt of and cancer recurrence or death. In total 112 (median age 54 years) underwent 114 procedures. The most common histological subtypes invasive ductal carcinoma (61.4%), lobular (13.2%) in situ (13.2%). Of patients, 88.2% had oestrogen receptor-positive 14% human epidermal growth factor cancer; 26.3% multifocal cancer. median size 30mm. Nottingham Prognostic Index 4.2. local rate 3.5% follow-up 8.6 years). 5- 10-year disease-free survival (DFS) 88.5% 83.5%, equivalent overall (OS) rates 94% 83.5%. Wound 23.6% (n=27), commonest being infection (11.4%; n=13) T-junction breakdown (10.5%; n=12). time 72 days (interquartile range [IQR] 56-90) with complications, 51 (IQR 42-58) those without. However, did not affect DFS OS (log-rank test; p=0.58 p=0.94, respectively). This confirmed on Cox regression analysis. Our study finding demonstrates that although complications after leads a modest therapy, long-term outcomes comparable without complications.